Researchers are excited about the medication , a groundbreaking dual agonist showing remarkable outcomes in early trials for body loss . It acts by targeting several pathways : GLP-1 and GIP, which , when https://ammariegc688974.blog-ezine.com/41308291/this-new-possibility-for-size-loss